The FDA granted orphan designation to Sanofi (SNY) US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA
- FDA approves Sanofi biosimilar product for treatment of diabetes
- Sanofi price target raised to EUR 110 from EUR 105 at JPMorgan
- Sanofi Ends E.coli Vaccine Trial Amid Efficacy Concerns
- Senate votes to confirm Robert Kennedy as head of HHS
Questions or Comments about the article? Write to editor@tipranks.com